Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Thyroid Neoplasms 3Thyroid Cancer, Papillary 2Adenocarcinoma, Follicular 2Thyroid Diseases 1Prostatic Neoplasms 1Lymphoma, T-Cell 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Hodgkin Disease 1Head and Neck Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 24fludarabine phosphate 22Filgrastim 15Gemcitabine 14fludarabine 13Rituximab 13Brentuximab Vedotin 13Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Vorinostat 11Tacrolimus 11Bortezomib 10Mycophenolic Acid 9Melphalan 9Etoposide 9Busulfan 9Sirolimus 8Lenalidomide 8Azacitidine 8Nivolumab 7Dexamethasone 7pembrolizumab 6Radiotherapy 6Cytarabine 6Antilymphocyte Serum 6romidepsin 5aldesleukin 5Panobinostat 5Leucovorin 5Doxorubicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hodgkin Disease × Iodine-131 × Clear all
NCT00860171 2020-04-03

Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Terminated
16 enrolled 10 charts
Lymphoid

Hodgkin Disease, Lymphoma, B-Cell, Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡